NetobiminCAS# 88255-01-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 88255-01-0 | SDF | Download SDF |
PubChem ID | 71449 | Appearance | Powder |
Formula | C14H20N4O7S2 | M.Wt | 420.5 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-[[(methoxycarbonylamino)-(2-nitro-5-propylsulfanylanilino)methylidene]amino]ethanesulfonic acid | ||
SMILES | CCCSC1=CC(=C(C=C1)[N+](=O)[O-])NC(=NCCS(=O)(=O)O)NC(=O)OC | ||
Standard InChIKey | WCBVUETZRWGIJQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C14H20N4O7S2/c1-3-7-26-10-4-5-12(18(20)21)11(9-10)16-13(17-14(19)25-2)15-6-8-27(22,23)24/h4-5,9H,3,6-8H2,1-2H3,(H,22,23,24)(H2,15,16,17,19) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Netobimin Dilution Calculator
Netobimin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3781 mL | 11.8906 mL | 23.7812 mL | 47.5624 mL | 59.453 mL |
5 mM | 0.4756 mL | 2.3781 mL | 4.7562 mL | 9.5125 mL | 11.8906 mL |
10 mM | 0.2378 mL | 1.1891 mL | 2.3781 mL | 4.7562 mL | 5.9453 mL |
50 mM | 0.0476 mL | 0.2378 mL | 0.4756 mL | 0.9512 mL | 1.1891 mL |
100 mM | 0.0238 mL | 0.1189 mL | 0.2378 mL | 0.4756 mL | 0.5945 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- R1530
Catalog No.:BCC1879
CAS No.:882531-87-5
- AI-3
Catalog No.:BCC8018
CAS No.:882288-28-0
- P005091
Catalog No.:BCC1287
CAS No.:882257-11-6
- H-Ile-OAll.TosOH
Catalog No.:BCC2963
CAS No.:88224-05-9
- H-Leu-OAll.TosOH
Catalog No.:BCC2969
CAS No.:88224-03-7
- Notopterol
Catalog No.:BCN5386
CAS No.:88206-46-6
- (-)-Chelidonine
Catalog No.:BCN7456
CAS No.:88200-01-5
- Clofibric Acid
Catalog No.:BCC4652
CAS No.:882-09-7
- iMDK
Catalog No.:BCC6365
CAS No.:881970-80-5
- MDL 28170
Catalog No.:BCC2352
CAS No.:88191-84-8
- 3,5,9-Trihydroxyergosta-7,22-dien-6-one
Catalog No.:BCN1318
CAS No.:88191-14-4
- Levistilide A
Catalog No.:BCN1197
CAS No.:88182-33-6
- AMG-47A
Catalog No.:BCC6394
CAS No.:882663-88-9
- Polygalasaponin F
Catalog No.:BCN2317
CAS No.:882664-74-6
- HC 067047
Catalog No.:BCC7861
CAS No.:883031-03-6
- CCG 50014
Catalog No.:BCC4897
CAS No.:883050-24-6
- BI 78D3
Catalog No.:BCC8089
CAS No.:883065-90-5
- E 64d
Catalog No.:BCC1127
CAS No.:88321-09-9
- N-Benzyllinolenamide
Catalog No.:BCN6531
CAS No.:883715-18-2
- N-Benzyloleamide
Catalog No.:BCN1317
CAS No.:101762-87-2
- (9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide
Catalog No.:BCN1316
CAS No.:883715-22-8
- DPDPE
Catalog No.:BCC5758
CAS No.:88373-73-3
- Adrenorphin
Catalog No.:BCC1021
CAS No.:88377-68-8
- 8-Lavandulylkaempferol
Catalog No.:BCN3961
CAS No.:883859-83-4
Pharmacological assessment of netobimin as a potential anthelmintic for use in horses: plasma disposition, faecal excretion and efficacy.[Pubmed:19022462]
Res Vet Sci. 2009 Jun;86(3):514-20.
This study aimed to determine the plasma disposition and faecal excretion of Netobimin (NTB) and its respective metabolites as well as the efficacy against strongyles in horses following oral administration. Netobimin (10mg/kg) was administered orally to 8 horses. Blood and faecal samples were collected from 1 to 120h post-treatment and analysed by high performance liquid chromatography (HPLC). Using a chiral phase-based HPLC, plasma disposition of ABZSO enantiomers produced was also determined. Faecal strongyle egg counts (EPG) were performed by a modified McMaster's technique before and after the treatment. Neither NTB nor ABZ were present and only albendazole sulphoxide (ABZSO) and sulphone metabolites (ABZSO(2)) were detected in the plasma samples. Maximum plasma concentration of ABZSO (0.53+/-0.14microg/ml) and ABZSO(2) (0.36+/-0.09microg/ml) were observed at (t(max)) 10.50 and 19.50h, respectively following administration of NTB. The area under the curve (AUC) of the two metabolites was similar to each other. Netobimin was not detected, and ABZ was predominant in faecal samples. The maximum plasma concentration (C(max)) of (-)ABZSO was significantly higher than (+)ABZSO, but the area under the curves (AUCs) of the enantiomer were not significantly different each other in plasma samples. The enantiomers of ABZSO were close to racemate in the faecal samples analyzed. Netobimin reduced the EPG by 100%, 100%, 77%, 80% and 75% 2, 4, 6, 8 and 10 weeks post-treatment, respectively. The specific behaviour of the two enantiomers probably reflects different enantioselectivity of the enzymatic systems of the liver which are responsible for sulphoxidation and sulphonation of ABZ. Considering the pharmacokinetic and efficacy parameters NTB could be used as an anthelmintic in horses.
Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.[Pubmed:17004041]
Vet Res Commun. 2006 Oct;30(7):791-805.
Netobimin (NTB) was administered orally to ewes at 20 mg/kg bodyweight. Blood and faecal samples were collected from 1 to 120 h post-treatment and analysed by high-performance liquid chromatography (HPLC). Using a chiral phase-based HPLC, plasma disposition of albendazole sulphoxide (ABZSO) enantiomers produced was also determined. Neither NTB nor albendazole (ABZ) was present and only ABZSO and albendazole sulphone (ABZSO(2)) metabolites were detected in the plasma samples. Maximum plasma concentrations (C(max)) of ABZSO (4.1 +/- 0.7 microg/ml) and ABZSO(2) (1.1 +/- 0.4 microg/ml) were detected at (t(max)) 14.7 and 23.8 h, respectively following oral administration of Netobimin. The area under the curve (AUC) of ABZSO (103.8 +/- 22.8 (microg h)/ml) was significantly higher than that ABZSO(2)(26.3 +/- 10.1 (microg h)/ml) (p < 0.01). (-)-ABZSO and (+)-ABZSO enantiomers were never in racemate proportions in plasma. The AUC of (+)-ABZSO (87.8 +/- 20.3 (microg h)/ml) was almost 6 times larger than that of (-)-ABZSO (15.5 +/- 5.1 (microg h)/ml) (p < 0.001). Netobimin was not detected, and ABZ was predominant and its AUC was significantly higher than that of ABZSO and ABZSO(2), following NTB administration in faecal samples (p > 0.01). Unlike in the plasma samples, the proportions of the enantiomers of ABZSO were close to racemic and the ratio of the faecal AUC of (-)-ABZSO (172.22 +/- 57.6 (microg h)/g) and (+)-ABZSO (187.19 +/- 63.4 (microg h)/g) was 0.92. It is concluded that NTB is completely converted to ABZ by the gastrointestinal flora and absorbed ABZ is completely metabolized to its sulphoxide and sulphone metabolites by first-pass effects. The specific behaviour of the two enantiomers probably reflects different enantioselectivity of the enzymatic systems of the liver that are responsible for sulphoxidation and sulphonation of ABZ.
Effect of fasciolicides on the antigenaemia in sheep naturally infected with Fasciola hepatica.[Pubmed:11510995]
Parasitol Res. 2001 Aug;87(8):609-14.
A study was developed to evaluate the influence of triclabendazole (Fasinex) and Netobimin (Hapasil) the antigenaemia in sheep naturally infected with Fasciola hepatica during 16 weeks. A sandwich-ELISA (enzyme-linked immunosorbent assay) using a rabbit polyclonal IgG antibody to F. hepatica antigens was employed and the data obtained were compared to those from coprological and indirect-ELISA techniques. Triclabendazole reduced the values of circulating antigens at weeks 2-4 post-treatment and faecal output at weeks 2-8 post-treatment, but antibodies showed positive values until the end of the study. Netobimin did not reduce circulating antigens of the trematode nor egg-excretion; and IgG antibodies did not decrease throughout the study.